LONDON – PTC Therapeutics Inc.'s muscular dystrophy therapy Translarna (ataluren; ID428) has survived intense scrutiny by the National Institute of Clinical and Care Excellence (NICE) to emerge with a recommendation that it is funded under a managed access agreement.